Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 9/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | HTR6 | P50406 | 4/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MGLL | Q99685 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5243267 | 1.00 | SIRT6 (0.68) | SIRT6ALDH1A1MAPTLMNAHTR6 | |
| SCHEMBL939887 | 0.95 | SIRT6 (0.74) | SIRT6ALDH1A1MAPTHTR6MAPK1 | |
| Hydrochloric Acid SCHEMBL591979 | 0.89 | SIRT6 (0.57) | SIRT6ALDH1A1MAPTLMNAHTR6 | |
| SCHEMBL40110 | 0.87 | HPGD (0.62) | SIRT6ALDH1A1MAPTLMNAMAPK1 | |
| SCHEMBL10743621 | 0.84 | SIRT6 (0.74) | SIRT6ALDH1A1MAPTHTR6MAPK1 | |
| SCHEMBL591154 | 0.84 | SIRT6 (0.64) | SIRT6ALDH1A1MAPTHTR6MAPK1 | |
| Hydrochloric Acid SCHEMBL590998 | 0.83 | SIRT6 (0.63) | SIRT6ALDH1A1MAPTHTR6MAPK1 | |
| SCHEMBL13312473 | 0.83 | SIRT6 (0.73) | SIRT6ALDH1A1MAPTHTR6MAPK1 | |
| SCHEMBL1414256 | 0.82 | MAPT (0.60) | SIRT6ALDH1A1MAPTMGLL | |
| SCHEMBL22652232 | 0.81 | SIRT6 (1.00) | SIRT6ALDH1A1MAPTHTR6MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275022-A1 | Substituted Quinazolones as Anti-Cancer Agents | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | US | disclosed |
| EP-1761506-A1 | SUBSTITUTED QUINAZOLONES AS ANTI-CANCER AGENTS | AstraZeneca AB (SE) | 2007-03-14 | — | — | EP | disclosed |
| WO-2005123696-A1 | SUBSTITUTED QUINAZOLONES AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275022-A1 | Substituted Quinazolones as Anti-Cancer Agents | BRAF, NRAS, RAF1 | SIRT6 988/4885ALDH1A1 619/4885MAPT 4484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.